Tag: Alzheimer’s
House Committees to Investigate New Alzheimer Disease Drug Approval
FDA approved Aduhelm earlier this month, despite advisory committee's conclusion that there was not enough evidence to support its effectiveness
Lilly to Seek FDA Approval for New Drug for Alzheimer Disease
Donanemab has already received a 'breakthrough therapy' designation from the FDA
Three FDA Advisers Quit Over Agency Approval of Aduhelm
Several experts have said the available evidence about Aduhelm raises significant doubts about its effectiveness
FDA Approves Aduhelm for Alzheimer Disease
Agency says it has granted approval on the condition that drug maker Biogen conduct a new clinical trial
Donanemab Studied in Early Symptomatic Alzheimer Disease
Slightly less cognitive and functional decline seen with donanemab versus placebo at 76 weeks in phase 2 trial
AAN: Prior Psych Diagnosis Tied to Younger Age of Alzheimer Onset
Findings based on data from retrospective chart review of patients at tertiary specialty memory care center
Many Non-Whites Experience Discrimination in Alzheimer Disease Care
Overall, 36, 19, and 18 percent of Black, Hispanic, Asian Americans, respectively, believe discrimination is barrier to receiving care
Prediabetes, Type 2 Diabetes Tied to Poorer Brain Health
Higher risk for cognitive decline, vascular dementia, Alzheimer disease seen with high blood glucose
White Matter Hyperintensities Characterized in Dementia
Association seen for larger volumes of white matter hyperintensities with disease severity, but not vascular risk, in bvFTD
Half of Alzheimer Disease Dementia Cases Are Mild
Among Framingham Heart Study participants, one in five cases were severe
